Although metabolic disorder has been widely accepted to become a critical risk factor of cardiovascular diseases (CVDs), the mechanisms underlying the promotional effects of metabolic disorder on CVDs are not fully understood. As the central part of inter-organ communication, metabolic organs not only regulate blood glucose and blood lipid levels, but also secrete many metabolic regulatory factors, such as fibroblast growth factor (FGF) 21, angiopoietin-like 4 (ANGPTL4), retinol-binding protein 4 (RBP4) secreted by the liver, adiponectin and leptin secreted by adipose tissue, myostatin and irisin secreted by muscle tissue, etc. These regulatory factors can regulate the structure and function of the heart and blood vessels, thus playing a vital role in the occurrence of CVDs (1). This Research Topic entitled "The Regulatory Role of Metabolic Organ-Secreted Factors in the Development of Cardiovascular Diseases" received 3 original articles and 2 review articles. This special issue focuses on recent findings to investigate the relationship between metabolic secretory factors and CVDs.The metabolic syndrome (Mets) is related to a higher risk of cardiovascular outcomes and allcause mortality(2). Emerging evidence demonstrate that chronic short sleep may disturb the metabolism and result in adverse health outcomes, including hypertension, myocardial infarction (MI), stroke, coronary heart disease (CHD), diabetes mellitus, and impaired memory, which are regarded as risk factors for the progression of CVDs (3, 4). In this issue, Sun et al. found that short sleep duration is an independent risk factor for the development of CVDs, especially in people with Mets. In line with previous studies, this study suggests that the promotional effect of sleep deprivation on metabolic disorders should be related to low-level systemic inflammation induced by circadian rhythm disturbances. Similarly, our recent study has also determined that the liver would be the main source of low-level systemic inflammation that contributes to the development of saltinduced hypertension, as inhibiting hepatic steatosis and inflammation by metformin helped to relieve the elevated blood pressure and subsequent cardiovascular damage under high salt loading 38These studies highlighted the metabolic organs as a potential therapeutic approach for controlling 39 CVDs.A growing number of epidemiological indicate that nonalcoholic fatty liver 41 (NAFLD) is strongly associated with an increased risk of major CVD events, independently of 42 cardiovascular factors(6-8). One of the possible reasons may be that the liver serves as 43 the most dynamic metabolic organ and its secretory function disorder exerts powerful 44 effects on metabolic processes both in the liver and in peripheral tissues(9
Editorial13 July 2023
Editorial: The regulatory role of metabolic organ-secreted factors in the development of cardiovascular diseasesBackground: Pathological cardiac hypertrophy is commonly resulted from sustained pressure overload and/or metabolic disorder and eventually leads to heart failure, lacking specific drugs in clinic. Here, we aimed to identify promising anti-hypertrophic drug(s) for heart failure and related metabolic disorders by using a luciferase reporter-based high-throughput screening.
Methods: A screen of the FDA-approved compounds based on luciferase reporter was performed, with identified luteolin as a promising anti-hypertrophic drug. We systematically examined the therapeutic efficacy of luteolin on cardiac hypertrophy and heart failure in vitro and in vivo models. Transcriptome examination was performed to probe the molecular mechanisms of luteolin.
Results: Among 2570 compounds in the library, luteolin emerged as the most robust candidate against cardiomyocyte hypertrophy. Luteolin dose-dependently blocked phenylephrine-induced cardiomyocyte hypertrophy and showed extensive cardioprotective roles in cardiomyocytes as evidenced by transcriptomics. More importantly, gastric administration of luteolin effectively ameliorated pathological cardiac hypertrophy, fibrosis, metabolic disorder, and heart failure in mice. Cross analysis of large-scale transcriptomics and drug-target interacting investigations indicated that peroxisome proliferator activated receptor γ (PPARγ) was the direct target of luteolin in the setting of pathological cardiac hypertrophy and metabolic disorders. Luteolin can directly interact with PPARγ to inhibit its ubiquitination and subsequent proteasomal degradation. Furthermore, PPARγ inhibitor and PPARγ knockdown both prevented the protective effect of luteolin against phenylephrine-induced cardiomyocyte hypertrophy in vitro.
Conclusion: Our data clearly supported that luteolin is a promising therapeutic compound for pathological cardiac hypertrophy and heart failure by directly targeting ubiquitin-proteasomal degradation of PPARγ and the related metabolic homeostasis.

